Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice

Interferon-free treatment with daclatasvir plus sofosbuvir, with or without ribavirin, led to sustained virological response in a majority of people with genotype 3 hepatitis C virus (HCV) and

Published
20 November 2015
By
Liz Highleyman
New AbbVie hepatitis C combination cures 93 to 97% with genotype 3

A combination of two experimental direct-acting antivirals developed by AbbVie cured 93 to 97% of people with genotype 3 hepatitis C infection after a 12-week course of

Published
18 November 2015
By
Keith Alcorn
Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients

A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced, genotype 1 hepatitis C patients with cirrhosis, without the need

Published
18 November 2015
By
Liz Highleyman
Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation

A co-formulation of sofosbuvir and the pan-genotypic HCV NS5A inhibitor velpatasvir from Gilead Sciences produced sustained response in 99% of people with hepatitis C virus genotypes 1,

Published
17 November 2015
By
Liz Highleyman
Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients

A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the

Published
17 November 2015
By
Liz Highleyman
Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment

Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir, two studies

Published
17 November 2015
By
Keith Alcorn
New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study

A combination of two experimental direct-acting antivirals developed by AbbVie cured 97 to 100% of non-cirrhotic people with genotype 1 hepatitis C infection in a mid-stage phase

Published
16 November 2015
By
Keith Alcorn
Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3

An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a phase 2 study of people with difficult-to-treat hepatitis

Published
16 November 2015
By
Liz Highleyman
Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs

Merck's grazoprevir/elbasvir co-formulation cured hepatitis C infection in 92% of people who inject drugs (PWID) who received opioid substitution therapy in the C-EDGE CO-STAR study,

Published
16 November 2015
By
Liz Highleyman
Study suggests unprecedented 3-week hepatitis C cure

Yet another stunning victory in the drug battle against the liver-damaging hepatitis C virus (HCV) may be in the offing: A small study suggests it may be possible to cure some people of their infections in as few as 3 weeks.

Published
02 November 2015
From
Science

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close